<DOC>
	<DOCNO>NCT02066467</DOCNO>
	<brief_summary>The objective study collect clinical data safety performance ACUITY X4® lead use standard clinical setting . It prospective , non-randomized , observational multicenter study evaluate standard care . For Post Market Clinical Follow ( PMCF ) purpose 3 month implant success rate , adverse event basic parameter lead assess . The cohort subject include evaluation first 200 subject indicate PMCF Rally X4 receive ACUITY X4® lead implant . Study endpoint : Phrenic Nerve Stimulation ( PNS ) relate CFR 6 month post-implant ( Defined : rate freedom loss function operative system revision due unacceptable PNS threshold ) Lead-related Complication-Free Rate ( CFR ) Implant 3 month post-implant .</brief_summary>
	<brief_title>Maximizing CRT Delivery Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4 - RALLY X4 Study</brief_title>
	<detailed_description>Clinic visit occur : - Enrollment Consenting Clinic Visit ( ≤ 30 day prior implant procedure ) - Implant Procedure ( Day 0 ; future follow ups base date ) - Pre-Discharge Clinic Visit ( ≤ 7 day post implant procedure ) ( Required ) - One 6 Month Clinic Visit ( 20 180 day post implant procedure ) ( Required ) - Interim Visit ( ) ( Any time 1 6 Month Clinic Visit Close-out Clinic Visit ) ( Following study center specific standard care ) ( Device follow optional ) AE - reporting require - Close-out Clinic Visit ( 30 month ± 90 day , OR 180 day ± 90 day study close enrollment , whichever come first ) ( Required ) - During trial AEs , death , change device system must report - Devices subject receive Latitude device follow Boston Scientific ( BSC ) Latitude team . Device Data define Clinical Investigation Plan ( CIP ) , device alert , diagnostic data standard Latitude database may collect enter study database time .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Subject willing capable providing inform consent 2 . Subject plan implanted ACUITY X4® lead leftventricular pace sense via coronary venous system conjunction compatible BSC pulse generator 3 . Subject willing capable participate visit associate study approve clinical study center interval define CIP 4 . Subject age 18 , legal age give inform consent specific state national law 1 . Subjects hypersensitivity maximum single dose 0.51 mg dexamethasone acetate 2 . Subject enrol concurrent study without prior write approval BSC , exception local mandatory governmental registry observational studies/registries conflict affect following : Schedule procedure RALLY X4 Study ( i.e . cause additional miss visit ) ; RALLY X4 Study outcome ( i.e . involve medication could affect heart rate subject ) ; Conduct RALLY X4 Study per GCP/ ISO 14155:2011/ local regulation applicable 3 . Per implant physician 's discretion , subject suitable candidate receive study device determine implant procedure 4 . Women childbearing potential might pregnant time study enrollment ACUITY X4® lead implant . 5 . Subject unwilling unable participate schedule study follow visit approve study center 6 . Subject anticipate resident area schedule duration trial 7 . Subject 's physician allow participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Phrenic Nerve Stimulation</keyword>
	<keyword>Heartfailure treatment</keyword>
	<keyword>CRT-D therapy</keyword>
	<keyword>Quadripolar lead</keyword>
	<keyword>Lead related complication free rate</keyword>
</DOC>